13.3 CDC Childhood Immunization Schedules, Vaccine Safety & Catch-Up Guidelines

CDC Childhood Immunization Schedules, Vaccine Safety & Catch-Up Guidelines

Core Clinical Focus: Immunizations represent the single most impactful public health intervention in pediatric medicine, preventing devastating morbidity and mortality from infectious pathogens. The pediatric nurse must master chronological vaccination milestones, differentiate live from inactivated formulations, recognize absolute contraindications versus benign misconceptions, execute rapid anaphylaxis resuscitation, and adhere to federal documentation mandates.

---

1. Routine CDC Childhood & Adolescent Immunization Schedules

The Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) publishes annually updated childhood and adolescent immunization schedules.

Chronological vaccination milestones

Version check: On October 18, 2026, CDC's compliant schedule page identifies the July 2, 2025 schedule as current following a court stay of later changes. Use the live age table, catch-up table, notes, medical indications and addendum together. The list below is a learning framework, not a complete individualized order. CDC current schedule and version notice.

Birth

• Hepatitis B (HepB) #1: Administered within 24 hours of birth to all medically stable infants weighing $\ge 2,000\text{ grams}$.
  • Maternal HBsAg Positive Protocol: If mother is positive for Hepatitis B surface antigen (HBsAg+), administer HepB vaccine PLUS Hepatitis B Immune Globulin (HBIG, 0.5 mL) within 12 hours of birth at separate anatomical injection sites (e.g., opposite anterolateral thighs). Test infant for HBsAg and anti-HBs at 9 to 12 months of age.
  • Maternal HBsAg Unknown Protocol: Administer HepB vaccine within 12 hours of birth. Determine maternal HBsAg status immediately. If mother tests positive, administer HBIG as soon as possible, no later than age 7 days. For birth weight below 2,000 g with unknown maternal status, give both vaccine and HBIG within 12 hours and follow the additional-dose protocol; do not wait for the maternal result.

2 Months

• DTaP #1: Diphtheria, tetanus toxoids, and acellular pertussis.
• IPV #1: Inactivated poliovirus.
• Hib #1: Haemophilus influenzae type b.
• PCV #1: Pneumococcal conjugate vaccine (PCV15 or PCV20).
• Rotavirus (RV) #1: Oral live attenuated vaccine (RV1 [Rotarix, 2-dose] or RV5 [RotaTeq, 3-dose]).
• HepB #2: Administered between 1 and 2 months of age.

4 Months

• DTaP #2
• IPV #2
• Hib #2
• PCV #2
• Rotavirus #2

6 Months

• DTaP #3
• IPV #3: Can be administered between 6 and 18 months.
• Hib #3: Required if 4-dose formulation (ActHIB or Hiberix) is utilized; not required if 3-dose PedvaxHIB was used at 2 and 4 months.
• PCV #3
• Rotavirus #3: Required if RV5 (RotaTeq) is used; omitted if RV1 (Rotarix) was completed at 2 and 4 months.
• HepB #3: Can be administered between 6 and 18 months. Critical Rule: The final dose of the HepB series must not be given before 24 weeks of age (168 days) and at least 16 weeks after dose 1.
• Influenza (Annual): Routine annual influenza vaccination begins at 6 months of age.

12 to 15 Months

• MMR #1: Measles, mumps, rubella (live attenuated; minimum age: 12 months).
• Varicella (VAR) #1: Chickenpox (live attenuated; minimum age: 12 months).
• Hepatitis A (HepA) #1: Administered between 12 and 23 months; 2-dose series separated by at least 6 months.
• PCV #4 (Booster)
• Hib #3 or #4 (Booster)

15 to 18 Months

• DTaP #4: Verify the minimum interval from dose 3 and the catch-up notes.

4 to 6 Years (Kindergarten / School Entry)

• DTaP #5: Final booster dose (not required if dose 4 was given at age 4 years or older AND at least 6 months after dose 3).
• IPV #4: Final booster dose (must be given at $\ge 4\text{ years}$ of age and at least 6 months after the previous dose).
• MMR #2: Second dose for robust seroconversion.
• Varicella #2

11 to 12 Years (Preadolescent Visit)

• Tdap Booster: Tetanus, reduced diphtheria, and acellular pertussis (replaces childhood DTaP).
• MenACWY #1: Meningococcal conjugate vaccine (serogroups A, C, W, Y).
• Human Papillomavirus (HPV): Prevents cervical, anogenital, and oropharyngeal cancers.
  • 2-Dose Schedule: If series is initiated before the 15th birthday, only 2 doses are required, administered at 0 and 6 to 12 months (minimum interval: 5 months).
  • 3-Dose Schedule: If series is initiated on or after the 15th birthday, or in immunocompromised individuals (regardless of age), 3 doses are required, administered at 0, 1 to 2, and 6 months.

16 Years (Adolescent Visit)

• MenACWY #2 (Booster): Administered at age 16. (If the first dose was given at age 16 or older, no booster is required).
• MenB (Meningococcal Serogroup B): Bexsero (2-dose) or Trumenba (2- or 3-dose) administered under shared clinical decision-making, preferred at age 16 to 18 years.

Annual Influenza Special Dosing Rules

All children $\ge 6\text{ months}$ of age should receive annual influenza vaccination. Children aged 6 months through 8 years receiving the influenza vaccine for the first time in their lives (or who have received only 1 dose previously) require TWO doses separated by at least 4 weeks (28 days) during that initial season to establish protective antibody titers.

---

Master Reference Table: CDC Pediatric Immunization Schedule

---

2. Vaccine Classifications, True vs. False Contraindications

Understanding the biological composition of vaccines is essential to determine safety profiles in immunocompromised or high-risk pediatric populations.

Biological Vaccine Classifications

• Live Attenuated Vaccines: Contain living microorganisms weakened in the laboratory so they replicate in the recipient to stimulate vigorous humoral and cell-mediated immunity without producing full-blown clinical disease in immunocompetent hosts. Examples: MMR, Varicella (VAR), Rotavirus (RV), and Intranasal Live Attenuated Influenza Vaccine (LAIV / Flumist).
• Inactivated / Subunit / Toxoid / Conjugate Vaccines: Contain killed bacteria/viruses, protein subunits, bacterial toxins altered into harmless toxoids (tetanus, diphtheria), or capsular polysaccharides chemically conjugated to a carrier protein to elicit T-cell dependent immune memory in infants (Hib, PCV, MenACWY). These vaccines cannot replicate or cause infectious disease.

True Absolute Contraindications to Live Attenuated Vaccines

Live viral vaccines are strictly contraindicated under the following conditions:

1. Severe Congenital or Acquired Immunodeficiency: Severe Combined Immunodeficiency (SCID), agammaglobulinemia, hypogammaglobulinemia, active leukemia, lymphoma, generalized malignancies, or solid organ transplant immunosuppression. Replicating vaccine viruses can produce disseminated, lethal infections.
2. High-Dose Systemic Corticosteroid Therapy: Defined by the CDC as receiving $\ge 2\text{ mg/kg/day}$ or $\ge 20\text{ mg/day}$ of prednisone equivalent for $\ge 14\text{ consecutive days}$.
   • Live vaccines must be deferred during therapy and for at least 1 month (28 days) following cessation of high-dose steroids.
   • Permissible Steroids: Physiologic replacement therapy, low-dose daily therapy ($<2\text{ mg/kg/day}$), alternate-day therapy, topical/dermatologic steroids, inhaled corticosteroids, intra-articular injections, or short systemic bursts ($<14\text{ days}$) are NOT contraindications to live vaccines.
3. Severe HIV Immunosuppression: Severe CD4 T-lymphocyte depletion defined as:
   • Children $<5\text{ years}$: CD4 percentage $<15\%$.
   • Children $\ge 5\text{ years}$: Absolute CD4 count $<200\text{ cells/}\mu\text{L}$.
   • Critical Exception: Children with HIV who are NOT severely immunocompromised (CD4 $\ge 15\%$ and $\ge 200\text{ cells/}\mu\text{L}$) SHOULD receive MMR and Varicella, when the specific vaccine's age, sustained immune-status, and other eligibility criteria are met. HIV does not make wild-type infection uniformly fatal, and a single generic threshold does not replace the vaccine-specific assessment.
4. Pregnancy: Theoretical risk of live vaccine virus transmission to the fetus (avoid pregnancy for 28 days post-MMR/Varicella).
5. Prior Anaphylaxis: Severe anaphylactic reaction to a previous dose or known vaccine component (e.g., neomycin or gelatin in MMR/Varicella).

Rotavirus Vaccine Specific Contraindications & Strict Age Ceilings

• Absolute Contraindication: History of Intussusception. A documented history of intussusception is an absolute contraindication to all rotavirus vaccines. Post-licensure surveillance identifies a small risk of intussusception (1 to 3 cases per 100,000 infants) within 7 days of vaccination. Children with prior intussusception have an elevated risk for recurrence.
• Absolute Contraindication: SCID. Rotavirus causes severe chronic diarrhea and wasting in infants with severe combined immunodeficiency.
• Strict Age Ceilings:
  • Dose 1 must NOT be initiated at or after 15 weeks 0 days of age (maximum age for dose 1 is 14 weeks 6 days).
  • The absolute maximum age for the final dose of any rotavirus vaccine is 8 months 0 days.
  • If an infant misses these age windows, the vaccine is permanently omitted.

Inactivated Vaccine Specific Contraindications

• Pertussis Component (DTaP / Tdap): The occurrence of encephalopathy (e.g., coma, prolonged seizures, altered level of consciousness) within 7 days of a previous pertussis vaccine not attributable to another cause is an absolute contraindication to future pertussis doses. Consult current CDC guidance for a nonpertussis schedule. Pediatric DT is no longer available in the United States; do not assume an older substitution instruction remains usable.

False / Invalid Contraindications (Exam Traps)

The following conditions are NOT contraindications and should NEVER delay vaccination:

• Mild Acute Illness: Mild upper respiratory infection, otitis media, or mild diarrhea, with or without low-grade fever ($<38.3^\circ\text{C} / 101^\circ\text{F}$). (Only moderate-to-severe acute febrile illness warrants temporary postponement until acute symptoms resolve).
• Current Antibiotic Therapy: Antibiotics do not interfere with viral replication or inactivated bacterial immunogens.
• Premature Birth: Preterm infants must be immunized according to their chronological age from birth (same schedule, same dose, without correction for gestational age).
• Breastfeeding: Breast milk does not diminish vaccine efficacy.
• Family History: Family history of adverse vaccine reactions, seizures, or Sudden Infant Death Syndrome (SIDS).
• Mild Local Reactions: Local soreness, redness, swelling, or low-grade fever following a previous dose.
• Multiple Vaccines on the Same Day: Administering multiple routine vaccines simultaneously does not overwhelm the immune system.

---

3. Catch-Up Principles, Vaccine Spacing & Administration Techniques

When a child falls behind schedule, the nurse must navigate catch-up guidelines without restarting completed series.

The Golden Catch-Up Principle

"Count the Doses, Not the Intervals": An interrupted vaccine series NEVER needs to be restarted, regardless of the duration elapsed since the last dose. If a 3-year-old child presents having received only 2-month vaccines, simply administer the next scheduled doses respecting minimum age and minimum interval rules.

The 28-Day Live Vaccine Spacing Rule

When administering two live injectable or live intranasal vaccines (e.g., MMR, Varicella, LAIV):

• They must either be administered SIMULTANEOUSLY on the same calendar day at separate anatomical injection sites, OR
• They must be separated by a minimum of 28 days (4 weeks).
• Invalid Dose Consequence: If two live vaccines are inadvertently administered less than 28 days apart, the immune system's transient interferon release from the first vaccine blunts viral replication of the second vaccine, rendering it non-immunogenic. The second dose is invalid and must be repeated at least 28 days after the invalid dose.

Anatomical Injection Sites & Needle Selection

1. Infants and Toddlers ($<12\text{ to }24\text{ months}$):
   • Preferred IM Site: Anterolateral thigh (vastus lateralis muscle). Needle: 1 inch (25 mm), 22 to 25 gauge, inserted at a 90-degree angle.
   • Absolute Prohibition: The dorsogluteal site must NEVER be used for infant immunizations due to high risk of sciatic nerve injury and variable subcutaneous fat thickness.
2. Older Children ($\ge 3\text{ years}$) and Adolescents:
   • Preferred IM Site: Deltoid muscle (acromion landmark). Needle: 1 to 1.25 inches (25 to 32 mm), 22 to 25 gauge.
3. Subcutaneous Injections (MMR, Varicella):
   • Needle: 5/8 inch (16 mm), 23 to 25 gauge, inserted at a 45-degree angle into the anterolateral thigh ($<12\text{ months}$) or upper outer triceps region ($\ge 12\text{ months}$).

---

Acute Anaphylaxis Emergency Recognition & Management

Vaccine-induced anaphylaxis is a rare ($~1\text{ to }2\text{ per million doses}$) but life-threatening emergency occurring within minutes of administration.

• Clinical Signs: Generalized hives (urticaria), facial angioedema, lip/tongue swelling, stridor, wheezing, dyspnea, tachycardia, hypotension, and circulatory collapse.
• First-Line Medication: INTRAMUSCULAR EPINEPHRINE (1:1,000 concentration / 1 mg/mL).
  • Pediatric Dosage: 0.01 mg/kg (0.01 mL/kg).
  • Maximum Single Dose: 0.3 mg (0.3 mL) in prepubertal children; 0.5 mg (0.5 mL) in adolescents/adults.
  • Administration Site: Anterolateral mid-thigh (vastus lateralis). IM injection into the thigh produces faster, higher peak plasma epinephrine levels than subcutaneous injection or deltoid injection.
  • Repeat Dosing: Repeat every 5 to 15 minutes as needed for persistent or refractory symptoms.
• Patient Positioning & Support: Place patient supine with legs elevated (unless airway compromise necessitates upright sitting); administer high-flow oxygen via non-rebreather mask; establish IV access and administer normal saline bolus (20 mL/kg) for hypotension.
• Secondary Adjuncts (Never Replace Epinephrine): Antihistamines (diphenhydramine 1 mg/kg IV) and corticosteroids (methylprednisolone 1 to 2 mg/kg IV) are secondary adjuncts to treat cutaneous urticaria when specifically indicated; they have not been shown reliably to prevent biphasic anaphylaxis. They do not reverse airway obstruction or vascular shock; epinephrine must never be delayed to give antihistamines.

---

4. Vaccine Safety, Regulatory Mandates & Legal Frameworks

The National Childhood Vaccine Injury Act (NCVIA) of 1986 establishes strict federal legal mandates for vaccine administration in the United States.

Vaccine Information Statements (VIS)

• Federal Legal Mandate: Under federal law, healthcare providers must provide the most current CDC Vaccine Information Statement (VIS) to the parent or legal guardian PRIOR to the administration of EACH dose of every covered vaccine.
• Informed Consent Discussion: Providers must allow the parent/guardian adequate time to read the VIS and ask questions regarding risks, benefits, and common side effects before administering the vaccine.

Mandatory Medical Record Documentation

For covered vaccines, federal requirements include administration date, manufacturer, lot number, administrator identifying information, and the VIS edition and provision dates. The following expanded clinical record also includes safety and administration details required by product instructions, local rules or good practice; they are not eight identical federal requirements for every vaccine:

1. Date of administration (month, day, year).
2. Vaccine manufacturer.
3. Vaccine lot number.
4. Expiration date of the vaccine vial.
5. Anatomical site and route of administration (e.g., right vastus lateralis, IM).
6. Publication / edition date of the VIS provided.
7. Date the VIS was provided to the parent/guardian.
8. Name, address, and professional title of the administering nurse.

Vaccine Adverse Event Reporting System (VAERS)

Co-administered by the CDC and the Food and Drug Administration (FDA), VAERS is a national post-marketing safety surveillance program.

• Reporting duties: Report events required by the applicable VAERS reportable-events table, manufacturer contraindications and relevant product/program requirements. CDC also encourages reporting clinically significant events and administration errors even when causality is uncertain; do not describe every event or every error as universally mandated under the same rule. A VAERS report does not establish that the vaccine caused the event. CDC VAERS surveillance guidance.
• Vaccine Injury Compensation Program (VICP): A federal no-fault alternative to civil litigation designed to provide compensation to individuals injured by childhood vaccines.

Source check

CDC child/adolescent schedule and notes, checked October 18, 2026. Verify product, age, indication, dose limits, and the applicable institutional order before clinical administration.

Completeness check: Before administering any vaccine, also assess current COVID-19, RSV, travel, exposure, medical-risk and catch-up recommendations as applicable. A routine-age table alone is insufficient. MMR/varicella route, influenza priming, MenB intervals, and high-risk schedules require product-specific notes. CDC MMR product routes.